hcv evolution: diversification and convergence yury khudyakov division of viral hepatitis centers...

40
HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Upload: betty-george

Post on 16-Dec-2015

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

HCV Evolution: Diversification and Convergence

Yury Khudyakov

Division of Viral HepatitisCenters for Disease Control and Prevention, Atlanta, GA

Page 2: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Public Health

Reduction of morbidity and mortality

- Diagnostics- Treatment- Prevention

Medicine

Introduction

Page 3: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

A high rate of mutation defines rapid HCV evolution

HCV genome continuously changes

“Arms Race”

Pervasive coevolution

Opportunity for convergence

Introduction

Page 4: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

PHYLOGENETIC ANALYSISIntra-Host HCV Variants

Patient 1

Patient 2

Patient 3

Patient 4

Page 5: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Network of coordinated substitutions in the HCV polyprotein

K-Core Decomposition of HCV Network

Page 6: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network of HCV Polyprotein Site Interactions and Therapy Outcome

Page 7: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network associating the HVR1 sites with IFN response and host demographic factors

HVR1-BN

Page 8: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Intra-Host Evolution over

Many Years

Page 9: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

15.991aIDUFemaleUnknownD

15.961aUnknownMaleBlackC

18.121aIDUFemaleBlackB

8.841bTransfusionMaleWhiteA

YearsGenotypeTransmissionGenderRacePatient ID

Sentinel County HCV Follow-up Study

Page 10: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

0.0 5.0 10.0 15.0

0.00

10.00

20.00

Div

erge

nce

Time

DBA C

HCV Quasispecies Divergence During Long-Term Chronic Infection

Patients

Page 11: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

HVR1: patient A

Time-pints (Yrs)

0

8.8

2.8

7.92.3

0-2.8 yr

7.9-8.8 yr

HVR1: patient B

0

17.218.2

11.2

15.3

12.213.4

10.19.07.93.33.02.8

16.2

Time-points (Yrs) 0 - 3.3 yr

7.9-13.4

7.9-17.2

15.3-18.2

HVR1: patient DTime-points (Yrs)

0

16.0

1.5

2.52.74.8

2.3

1.62.0

11.612.114.015.0

1.5-2.7 yr

4.8-16.0 yr

HVR1: patient CTime-points (Yrs)

0

9.0

16.0

7.1

15.0

8.1

14.6

10.5

0.3

11.1

0-0.3 yr

7.1-8.1 yr

9.0-16.0 yr

HVR1 Phylogenetic Trees

Page 12: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

DBA C

0.0 5.0 10.0 15.0

0.00

0.50

1.00

1.50

2.00

dN/d

S

Time

Changes in Selection Pressures Over Time

dN/dS vs. TimeHVR1 – R=-0.58, p=0.0001NS5A – R=-0.61, p=0.0001

Titer vs. TimeR=0.585, p=0.0001

Titer vs. dN/dSR=-0.383, p=0.012

Patients

Page 13: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 14: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 15: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 16: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 17: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 18: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 19: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 20: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 21: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 22: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA
Page 23: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Genetic Linkage to Viral and Host Factors

Genomic StructureQS diversity

HCV QS SEQUENCE HOST

Viral titer

dN/dS

HCV QS SEQUENCE Factors

Page 24: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

I. Molecular Epidemiologic Data• NHANESIII:

• 106 patients• 1384 HVR1 quasispecies; Genotypes 1 – 6• HVR1: positions 1491 to 1577nt (polyprotein 488 to 516)• 5’UTR: positions 127 to 340nt• NS5B: positions 8290 to 8589nt (polyprotein 2651 to 2749)

II. Quantitative Structure Relationships• Probabilistic Graphical Models:

• Bayesian Networks (BN)

III. Predictions• Causal models:

• BN classifiers

Page 25: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network Model Associating Sequences of HCV HVR1 Quasispecies to Viral and Host Parameters

Page 26: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network Model Associating Sequences of HCV HVR1 Quasispecies to Viral and Host Parameters

Page 27: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network Model Associating Sequences of HCV HVR1 Quasispecies to Viral and Host Parameters

Page 28: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Bayesian Network Model Associating Sequences of 3 HCV Genome Regions to Viral and Host Parameters

Page 29: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Target classes 10-fold-CV ‡

(%) Acc.randTest †

(10-fold-CV ‡)TestSet**

Genotype 99.9% 0.3286 100%

dN/dS^^ (3-bin) (2-bin)

94.4%92.2%

0.4020 0.5120

70.3%82.7%

NQSaa-hvr1 88.0% 0.3887 70.3%

NQSnt-hvr1 87.7% 0.3978 72.4%

Viral Titer 97.2% 0.6031 52.40%

‡ Avg. accuracies† Random assignment of class labels** 10 NHANES-3 patients; 5M and 5F; Genotypes 1a and 1b; 185nt/96aa HVR1 QS^^ Based on dNdS 3 class or 2 class grouping

Quantitative Validation of Models

Predictions: Classification Modeling

Page 30: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Five physicochemical properties (Atchley et al, 2005):

Polarity, α-helix , Size, aa frequency, Charge

Multiple sequence alignment

Euclidean distance between every pair of sequences

Visualization of distance matrix Pathfinder network (r = ∞, q = n-1)

Methods

Page 31: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

PFNET

Page 32: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Inter-genotype convergence

Genotype 1

Page 33: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Genotype 2

Inter-genotype convergence

Page 34: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

• 24.3% of all links are between different genotypes.

Genotype convergence

Page 35: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

• We immunized mice with 102 HVR1 peptides covering all high-density regions of the sequence space.

• We tested the reactivity of each sera against 262 peptides (in yellow), a total of 26724 reactions

Cross-reactivity experiment

Page 36: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

• There were 5039 positive reactions (blue links), which correspond to 18.85% of all tested.

Page 37: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

• Three peptides (yellow) were found that collectively reacted with all 262 antigens.

Page 38: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Relationship between the reduction of selection pressure and cross-immunoreactivity among HCV intra-host variants

Patient Correlation between DN/DS and ACR

p-value

Patient B -0.6262 0.0166Patient C -0.9101 0.0003Patient D -0.476 0.1001

60*ACR

DN/DS

Patient C

Page 39: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Public Health: Reduction of morbidity and mortality

- Diagnostics- Treatment- Prevention

Medicine:

Conclusion

Many viral phenotypic traits with significant medical and public healthimplications are convergent rather than ancestral

Page 40: HCV Evolution: Diversification and Convergence Yury Khudyakov Division of Viral Hepatitis Centers for Disease Control and Prevention, Atlanta, GA

Thank you!